Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 6/20 | 0.38 |
| ▸ | RARA | P10276 | 5/20 | 0.38 |
| ▸ | RARG | P13631 | 5/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10123720 | 0.90 | XDH (0.45) | — | |
| SCHEMBL10123679 | 0.86 | NR3C2 (0.40) | NOTUMNR3C2 | |
| SCHEMBL10123834 | 0.80 | XDH (0.46) | — | |
| SCHEMBL10123830 | 0.78 | XDH (0.44) | — | |
| SCHEMBL10123870 | 0.78 | EGLN1 (0.37) | NOTUMF11 | |
| SCHEMBL10123766 | 0.77 | RORC (0.46) | NR3C2 | |
| SCHEMBL10123731 | 0.75 | XDH (0.49) | — | |
| SCHEMBL10123707 | 0.75 | XDH (0.49) | — | |
| SCHEMBL10123784 | 0.74 | XDH (0.40) | NR3C2RXRA | |
| SCHEMBL10123838 | 0.73 | XDH (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748452-B2 | Indolizine derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| US-8748452-B2 | Indolizine derivative and use thereof for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-06-10 | — | — | US | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015972-A1 | INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, INMT, PON1 | NOTUM 360/4885RARB 3497/4885RARA 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.